| Name | Title | Contact Details |
|---|
Home Health Care Management (HHCM) is the parent and management company for our family of home health care providers - Berks Visiting Nurse Association, Visiting Nurse Association of Pottstown and Vicinity, Greater Lehigh Valley Visiting Nurse Association, and Advantage Home Care.
Zip N Squeeze Products is a Yorba Linda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Welcome. Autonomic Technologies, Inc. (ATI) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company`s initial product, the ATI Neurostimulation System, is approved in Europe for the treatment of cluster headache. The ATI Neurostimulation System was voted #2 among the Cleveland Clinic’s top 10 medical innovations for 2013, and Autonomic Technologies was named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world.
Medical Leader is a Pikeville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.